表紙
市場調査レポート

概日リズム睡眠障害:パイプライン製品の分析

Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013

発行 Global Markets Direct 商品コード 246024
出版日 ページ情報 英文 40 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
概日リズム睡眠障害:パイプライン製品の分析 Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013
出版日: 2013年12月31日 ページ情報: 英文 40 Pages
概要

概日リズム睡眠障害とは、人体の概日リズム−−動物・植物の(約)24時間サイクルの生物学的プロセスを規定する「体内時計」−−が破壊された状態のことを指します。"概日" (Circadian) という言葉はラテン語起源で、文字通り「丸一日」ということを意味しています。この疾患の主な特徴は、睡眠パターンが恒常的または一時的に破壊されることです。その結果、「体内時計」の機能不全や、時間感覚や睡眠時間に関する「体内時計」と外部環境とのミスマッチが生じます。この疾患を発症した個人は、日中のあるときは不眠症を、またあるときは異常な眠気を訴えて、職場・学校・社会に適合しづらくなっていきます。

当レポートでは、世界各国での概日リズム睡眠障害治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

  • 分析範囲

概日リズム睡眠障害の概要

治療薬の開発

  • 概日リズム睡眠障害向けパイプライン製品:概要
  • 概日リズム睡眠障害向けパイプライン製品:比較分析

各企業で開発中の概日リズム睡眠障害治療薬

大学/研究機関で研究中の概日リズム睡眠障害治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

概日リズム睡眠障害治療薬:開発中の製品の一覧(企業別)

概日リズム睡眠障害治療薬:研究中の製品の一覧(大学/研究機関別)

概日リズム睡眠障害治療薬の開発に従事している企業

  • Pfizer Inc.
  • Neurim Pharmaceuticals Ltd.
  • Orphagen Pharmaceuticals, Inc.
  • Omeros Corporation

概日リズム睡眠障害:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別
  • 薬効分類別

薬剤のプロファイル

  • melatonin
  • Fibrate
  • PF-4800467
  • OPN4拮抗薬
  • 概日リズム睡眠障害向け治療薬

概日リズム睡眠障害治療薬:最新の薬剤プロファイル

概日リズム睡眠障害治療薬:開発が休止状態の製品

概日リズム睡眠障害関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全3件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC4392IDB

Global Markets Direct's, 'Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Circadian Rhythm Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Circadian Rhythm Sleep Disorders. Circadian Rhythm Sleep Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Circadian Rhythm Sleep Disorders.
  • A review of the Circadian Rhythm Sleep Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Circadian Rhythm Sleep Disorders pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Circadian Rhythm Sleep Disorders.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Circadian Rhythm Sleep Disorders pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Circadian Rhythm Sleep Disorders Overview
  • Therapeutics Development
    • Pipeline Products for Circadian Rhythm Sleep Disorders - Overview
    • Pipeline Products for Circadian Rhythm Sleep Disorders - Comparative Analysis
  • Circadian Rhythm Sleep Disorders - Therapeutics under Development by Companies
  • Circadian Rhythm Sleep Disorders - Therapeutics under Investigation by Universities/Institutes
  • Circadian Rhythm Sleep Disorders - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Circadian Rhythm Sleep Disorders - Products under Development by Companies
  • Circadian Rhythm Sleep Disorders - Products under Investigation by Universities/Institutes
  • Circadian Rhythm Sleep Disorders - Companies Involved in Therapeutics Development
    • Pfizer Inc.
    • Neurim Pharmaceuticals Ltd
    • Orphagen Pharmaceuticals, Inc.
    • Omeros Corporation
  • Circadian Rhythm Sleep Disorders - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
    • Assessment by Therapeutic Class
  • Drug Profiles
    • melatonin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Fibrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-4800467 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPN4 Antagonist - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug For Circadian Rhythm Sleep Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Circadian Rhythm Sleep Disorders - Recent Pipeline Updates
  • Circadian Rhythm Sleep Disorders - Dormant Projects
  • Circadian Rhythm Sleep Disorders - Product Development Milestones
    • Featured News & Press Releases
      • May 30, 2013: Vanda Pharma To Present Tasimelteon Non-24 Phase III Data At Two Medical Meetings
      • Mar 08, 2011: Vanda Pharmaceuticals Receives Orphan Drug Designation In Europe For Tasimelteon
      • Aug 26, 2010: Vanda Initiates Phase III Clinical Study Aimed At Resetting Body Clock
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Circadian Rhythm Sleep Disorders, H2 2013
  • Number of Products under Development for Circadian Rhythm Sleep Disorders - Comparative Analysis, H2 2013
  • Number of Products under Development by Companies, H2 2013
  • Number of Products under Investigation by Universities/Institutes, H2 2013
  • Comparative Analysis by Clinical Stage Development, H2 2013
  • Comparative Analysis by Early Stage Development, H2 2013
  • Products under Development by Companies, H2 2013
  • Products under Investigation by Universities/Institutes, H2 2013
  • Circadian Rhythm Sleep Disorders - Pipeline by Pfizer Inc., H2 2013
  • Circadian Rhythm Sleep Disorders - Pipeline by Neurim Pharmaceuticals Ltd, H2 2013
  • Circadian Rhythm Sleep Disorders - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2013
  • Circadian Rhythm Sleep Disorders - Pipeline by Omeros Corporation, H2 2013
  • Assessment by Monotherapy Products, H2 2013
  • Number of Products by Stage and Target, H2 2013
  • Number of Products by Stage and Mechanism of Action, H2 2013
  • Number of Products by Stage and Route of Administration, H2 2013
  • Number of Products by Stage and Molecule Type, H2 2013
  • Number of Products by Stage and Therapeutic Class, H2 2013
  • Circadian Rhythm Sleep Disorders Therapeutics - Recent Pipeline Updates, H2 2013
  • Circadian Rhythm Sleep Disorders - Dormant Projects, H2 2013

List of Figures

  • Number of Products under Development for Circadian Rhythm Sleep Disorders, H2 2013
  • Number of Products under Development for Circadian Rhythm Sleep Disorders - Comparative Analysis, H2 2013
  • Number of Products under Development by Companies, H2 2013
  • Comparative Analysis by Early Stage Products, H2 2013
  • Assessment by Monotherapy Products, H2 2013
  • Number of Products by Top 10 Target, H2 2013
  • Number of Products by Stage and Top 10 Target, H2 2013
  • Number of Products by Top 10 Mechanism of Action, H2 2013
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2013
  • Number of Products by Stage and Top 10 Molecule Type, H2 2013
  • Number of Products by Top 10 Therapeutic Class, H2 2013
  • Number of Products by Stage and Top 10 Therapeutic Class, H2 2013
Back to Top